Showing results (141-150 of 151) with videos related to
Sort By:
Pageof 16
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.Journal of Virology|May 5, 2017
Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion ProteinA Leemans, M De Schryver, W Van der Gucht, et al.AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.Vaccine|November 2, 2010
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood, P Costner, N Desai, et al.The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.Journal of Virology|January 28, 1998
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesR I Connor, B T Korber, B S Graham, et al.The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.Pageof 16